Analysis of U.S. Drug Patent 5,980,867: Scope, Claims, and Landscape

U.S. Patent 5,980,867, titled "Amide derivatives," was granted on November 9, 1999. The patent describes and claims novel amide compounds, their synthesis, and their use in treating various medical conditions, primarily related to cardiovascular and inflammatory diseases. The primary assignee of this patent is Merck & Co., Inc.

What is the Core Technology Protected by Patent 5,980,867?

The patent protects a specific class of chemical compounds: amide derivatives. These compounds are characterized by a particular chemical structure, detailed in the claims. The patent claims also encompass methods for synthesizing these compounds and their therapeutic applications.

The abstract of the patent states that it concerns "novel amide derivatives, useful for the treatment of cardiovascular and inflammatory diseases, as well as methods for preparing them." The Specification provides extensive detail on the chemical structure, including substituent groups (R1, R2, R3, R4, etc.) and their allowed variations. This structural specificity is central to the patent's scope, defining the boundaries of infringement.

What Are the Key Claims of Patent 5,980,867?

Patent 5,980,867 contains multiple claims, each defining a specific aspect of the protected invention. The core claims define the chemical compounds themselves, while dependent claims further refine the scope by specifying particular substituents or preferred embodiments.

Claim 1, the broadest independent claim, defines the compounds. It recites a generic formula for the amide derivatives, specifying various possible substituents. For example, it defines the nature of several R groups and heterocyclic rings that can be part of the molecular structure. This claim sets the fundamental scope of the patent, covering all compounds that fit this structural definition.

Dependent claims such as Claim 2 and Claim 3 further narrow the scope by specifying particular preferred substituents or configurations of the R groups mentioned in Claim 1. These claims offer protection for specific, often more potent or bioavailable, variations of the core invention.

Claims related to methods of synthesis (e.g., Claims 7-10) protect the processes developed to create these amide derivatives. This prevents competitors from using the patented synthesis routes, even if they develop a non-infringing compound or use the patented compound in a non-infringing way.

Claims related to therapeutic use (e.g., Claims 11-15) cover the application of these compounds for treating specific diseases. These claims are crucial for pharmaceutical applications, preventing others from marketing or selling the patented compounds for the stated medical indications.

The patent covers not only the compounds themselves but also "pharmaceutically acceptable salts thereof," broadening the scope to include common formulations of the active pharmaceutical ingredient.

What is the Prior Art Landscape for Amide Derivatives in 1999?

The patent landscape for amide derivatives in 1999 was extensive. Amide bonds are fundamental in organic chemistry and are present in numerous natural and synthetic molecules, including proteins, peptides, and many pharmaceuticals. Prior art relevant to Patent 5,980,867 would include:

Existing amide-based pharmaceuticals: Numerous drugs already on the market utilized amide functionalities. Analysis of these would focus on structural similarities and differences.
Chemical literature and patents: Academic publications and other patents describing the synthesis and properties of various amide derivatives would be considered.
General chemical knowledge: Standard organic chemistry textbooks and reference materials would inform the understanding of common reactions and structural motifs.

The novelty and non-obviousness of the invention claimed in Patent 5,980,867 would have been assessed against this backdrop. The patent examiner would have evaluated whether the specific structural class and therapeutic applications described were sufficiently distinct from existing knowledge to warrant patent protection.

What are the Key Therapeutic Areas Addressed by Patent 5,980,867?

Patent 5,980,867 specifically targets the treatment of cardiovascular and inflammatory diseases. The Specification details the potential efficacy of these compounds in models of these conditions.

Examples of therapeutic applications described in the patent include:

Cardiovascular diseases: The patent suggests utility in conditions such as hypertension, heart failure, and thrombosis. Mechanisms of action explored in the patent may relate to influencing blood pressure, blood clotting, or cardiac function.
Inflammatory diseases: The compounds are proposed for use in treating inflammatory conditions like arthritis, asthma, and inflammatory bowel disease. The patent likely details inhibition of key inflammatory pathways or mediators.

The specific therapeutic targets and mechanisms of action would be elaborated upon within the patent's detailed description and biological data.

What is the Commercial Significance of Patent 5,980,867?

The commercial significance of U.S. Patent 5,980,867 is directly linked to the drugs that fall within its scope and their market performance. As a patent assigned to Merck & Co., Inc., it is highly probable that this patent covers key active pharmaceutical ingredients (APIs) developed and marketed by the company.

A significant drug associated with Merck that utilizes a related chemical scaffold and targets cardiovascular and inflammatory pathways is Vioxx (rofecoxib). While Vioxx is a COX-2 inhibitor, the chemical structure and therapeutic indications share some overlap with the broader class of compounds described in Patent 5,980,867. However, Vioxx itself was patented separately and faced market withdrawal due to cardiovascular risks.

The commercial value of such a patent is realized through:

Market exclusivity: The patent grants Merck the exclusive right to make, use, sell, and import the patented compounds for the duration of the patent term (typically 20 years from the filing date). This exclusivity allows for recoupment of R&D investments and profit generation.
Licensing revenue: Merck could license the patent to other companies for specific fields of use or geographical regions, generating royalty income.
Strategic R&D: The patent serves as a foundational piece of intellectual property, enabling further research and development of next-generation therapies based on the protected chemical class.

The patent's expiration date is critical for determining when generic competition can enter the market.

What is the Patent Expiration Timeline for U.S. Patent 5,980,867?

U.S. Patent 5,980,867 was granted on November 9, 1999. Under standard U.S. patent law, patents filed on or after June 8, 1995, have a term of 20 years from the earliest effective filing date. For this patent, the effective filing date would be the filing date of the provisional application or the non-provisional application if no provisional was filed. Assuming the filing date corresponds closely to the grant date for the purpose of a general estimation, the patent's term would likely extend approximately 20 years from its filing.

If the patent's earliest U.S. filing date was November 10, 1998 (one year prior to grant, a common scenario for non-provisional applications), the patent would expire on November 10, 2018. If it was filed earlier, e.g., as a provisional application, the expiration date would be 20 years from that earlier date.

The exact expiration date is crucial for competitors planning generic market entry. Post-grant challenges or extensions (such as those related to Hatch-Waxman Act for pharmaceutical products) could alter this timeline.

What is the Intellectual Property Landscape Surrounding This Patent?

The intellectual property landscape for a patent like 5,980,867 is dynamic and comprises:

Related Patents by Merck: Merck likely holds numerous patents covering specific compounds within the broader class defined by 5,980,867, as well as patents on formulations, methods of treatment, and manufacturing processes related to drugs derived from this core technology.
Competitor Patents: Other pharmaceutical companies may hold patents on structurally similar compounds or compounds targeting the same therapeutic areas. These can create blocking positions or necessitate cross-licensing agreements.
Generic Filings: As the patent term nears expiration, generic manufacturers will file Abbreviated New Drug Applications (ANDAs) and may challenge the validity of the patent through Paragraph IV certifications, initiating patent litigation.
Regulatory Exclusivities: In addition to patent protection, new chemical entities (NCEs) are often granted regulatory exclusivities (e.g., 5 years of market exclusivity under the Hatch-Waxman Act for NCEs in the U.S.) that can extend market protection beyond patent expiration.
Litigation: The patent may have been involved in or be subject to patent litigation to defend its validity or enforce its claims against alleged infringers.

Analyzing this landscape requires a deep dive into patent databases, litigation records, and regulatory filings.

How Can Competitors Design Around Patent 5,980,867?

Designing around U.S. Patent 5,980,867 involves developing compounds or therapeutic approaches that do not infringe upon the patent's claims. This can be achieved by:

Structural Modification: Creating amide derivatives that fall outside the precise generic formula and substituent definitions in Claim 1. This could involve altering key atoms, functional groups, or ring structures specified as essential elements of the claimed invention. For example, if a specific heterocyclic ring is claimed, using a different ring system would avoid infringement.
Alternative Therapeutic Mechanisms: Developing compounds that treat the same diseases but operate via entirely different biological pathways or targets, thus not falling under the "method of treatment" claims.
Different Salt Forms or Polymorphs: While "pharmaceutically acceptable salts" are claimed, exploring novel salt forms or polymorphs not covered by specific dependent claims or subsequent patents might be a strategy, although this is often a narrow path to freedom from infringement.
Non-infringing Synthesis Routes: If the patent claims specific synthesis methods, developing entirely new and independent manufacturing processes would be a way to avoid infringing those process claims.
Focusing on Unclaimed Indications: If the patent claims specific therapeutic uses, developing and marketing a compound for a disease not covered by the patent claims would be a design-around strategy.

A thorough freedom-to-operate (FTO) analysis is essential for any company seeking to enter this therapeutic space.

What are the Potential Implications of Patent 5,980,867 on Future R&D?

The existence and scope of U.S. Patent 5,980,867 have had several implications for future research and development in the field of amide derivatives for cardiovascular and inflammatory diseases:

Defined Research Space: The patent clearly delineates a specific area of chemical space and therapeutic application that was protected. This has guided where competitors could invest R&D resources without infringing.
Inspiration for Next-Generation Compounds: While blocking direct copying, the patent's disclosures can inspire researchers to develop improved compounds that address the limitations of the patented technology or discover novel biological activities within the broader chemical class. This often involves exploring the boundaries of the claimed structures or seeking compounds with better efficacy, safety profiles, or pharmacokinetic properties.
Focus on Alternative Targets: The patent's focus on certain mechanisms may have prompted researchers to explore entirely different therapeutic targets for cardiovascular and inflammatory diseases, diversifying the R&D pipeline away from the patented space.
Patent Expiration Strategy: The impending expiration of the patent has historically driven significant R&D efforts by generic manufacturers to develop bioequivalent versions of any drugs falling under its scope, and by innovator companies to develop follow-on products that extend market exclusivity.

The patent's lifecycle, from grant to expiration, shapes investment decisions and research priorities within the pharmaceutical industry.

Key Takeaways

U.S. Patent 5,980,867 protects a class of amide derivative compounds, their synthesis, and their use in treating cardiovascular and inflammatory diseases.
The patent's scope is defined by detailed chemical structures and therapeutic applications, with Merck & Co., Inc. as the primary assignee.
The patent expiration date, likely around November 2018 (depending on filing date), marks the end of market exclusivity and the potential for generic competition.
Design-around strategies for competitors involve structural modifications, exploration of alternative therapeutic mechanisms, or development of non-infringing synthesis routes.
The patent landscape is complex, including related patents, competitor IP, generic filings, and potential litigation.

Frequently Asked Questions

What specific chemical structure is defined by Claim 1 of U.S. Patent 5,980,867? Claim 1 defines a generic formula for amide derivatives with various specified substituent groups (R1, R2, R3, R4, etc.) and heterocyclic ring structures, which must be precisely met or fall within the defined variations to be covered.
Does U.S. Patent 5,980,867 cover methods of treating diseases beyond cardiovascular and inflammatory conditions? No, the patent explicitly states its utility and claims are primarily focused on the treatment of cardiovascular and inflammatory diseases, as detailed within its specification.
Can a generic company manufacture a drug that falls under the chemical structure of U.S. Patent 5,980,867 if the patent has expired? Yes, once the patent has expired, generic companies can manufacture and sell drugs that fall within the expired patent's claims, provided they meet all regulatory requirements and do not infringe on any other valid patents or exclusivities.
What is the typical duration of patent protection for a drug like one covered by U.S. Patent 5,980,867? The standard patent term in the U.S. is 20 years from the earliest effective filing date. For pharmaceutical patents, extensions (such as patent term adjustment or extensions under the Hatch-Waxman Act) may be granted to compensate for regulatory review delays, potentially extending the effective period of exclusivity.
If a company develops a compound with a similar but not identical structure, is it automatically considered infringing U.S. Patent 5,980,867? Infringement depends on whether the similar structure falls within the literal scope of the patent's claims or is covered by the doctrine of equivalents. A detailed claim construction analysis and comparison are necessary to determine infringement.

Citations

[1] U.S. Patent 5,980,867. (1999). Amide derivatives. Retrieved from United States Patent and Trademark Office.

Title:	Flunisolide aerosol formulations
Abstract:	Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
Inventor(s):	Tsi-Zong Tzou, Robert K. Schultz, Danna L. Ross
Assignee:	3M Innovative Properties Co
Application Number:	US09/110,796
Patent Claim Types: see list of patent claims	Formulation; Compound; Use; Delivery;
Patent landscape, scope, and claims:	Analysis of U.S. Drug Patent 5,980,867: Scope, Claims, and Landscape U.S. Patent 5,980,867, titled "Amide derivatives," was granted on November 9, 1999. The patent describes and claims novel amide compounds, their synthesis, and their use in treating various medical conditions, primarily related to cardiovascular and inflammatory diseases. The primary assignee of this patent is Merck & Co., Inc. What is the Core Technology Protected by Patent 5,980,867? The patent protects a specific class of chemical compounds: amide derivatives. These compounds are characterized by a particular chemical structure, detailed in the claims. The patent claims also encompass methods for synthesizing these compounds and their therapeutic applications. The abstract of the patent states that it concerns "novel amide derivatives, useful for the treatment of cardiovascular and inflammatory diseases, as well as methods for preparing them." The Specification provides extensive detail on the chemical structure, including substituent groups (R1, R2, R3, R4, etc.) and their allowed variations. This structural specificity is central to the patent's scope, defining the boundaries of infringement. What Are the Key Claims of Patent 5,980,867? Patent 5,980,867 contains multiple claims, each defining a specific aspect of the protected invention. The core claims define the chemical compounds themselves, while dependent claims further refine the scope by specifying particular substituents or preferred embodiments. Claim 1, the broadest independent claim, defines the compounds. It recites a generic formula for the amide derivatives, specifying various possible substituents. For example, it defines the nature of several R groups and heterocyclic rings that can be part of the molecular structure. This claim sets the fundamental scope of the patent, covering all compounds that fit this structural definition. Dependent claims such as Claim 2 and Claim 3 further narrow the scope by specifying particular preferred substituents or configurations of the R groups mentioned in Claim 1. These claims offer protection for specific, often more potent or bioavailable, variations of the core invention. Claims related to methods of synthesis (e.g., Claims 7-10) protect the processes developed to create these amide derivatives. This prevents competitors from using the patented synthesis routes, even if they develop a non-infringing compound or use the patented compound in a non-infringing way. Claims related to therapeutic use (e.g., Claims 11-15) cover the application of these compounds for treating specific diseases. These claims are crucial for pharmaceutical applications, preventing others from marketing or selling the patented compounds for the stated medical indications. The patent covers not only the compounds themselves but also "pharmaceutically acceptable salts thereof," broadening the scope to include common formulations of the active pharmaceutical ingredient. What is the Prior Art Landscape for Amide Derivatives in 1999? The patent landscape for amide derivatives in 1999 was extensive. Amide bonds are fundamental in organic chemistry and are present in numerous natural and synthetic molecules, including proteins, peptides, and many pharmaceuticals. Prior art relevant to Patent 5,980,867 would include: Existing amide-based pharmaceuticals: Numerous drugs already on the market utilized amide functionalities. Analysis of these would focus on structural similarities and differences. Chemical literature and patents: Academic publications and other patents describing the synthesis and properties of various amide derivatives would be considered. General chemical knowledge: Standard organic chemistry textbooks and reference materials would inform the understanding of common reactions and structural motifs. The novelty and non-obviousness of the invention claimed in Patent 5,980,867 would have been assessed against this backdrop. The patent examiner would have evaluated whether the specific structural class and therapeutic applications described were sufficiently distinct from existing knowledge to warrant patent protection. What are the Key Therapeutic Areas Addressed by Patent 5,980,867? Patent 5,980,867 specifically targets the treatment of cardiovascular and inflammatory diseases. The Specification details the potential efficacy of these compounds in models of these conditions. Examples of therapeutic applications described in the patent include: Cardiovascular diseases: The patent suggests utility in conditions such as hypertension, heart failure, and thrombosis. Mechanisms of action explored in the patent may relate to influencing blood pressure, blood clotting, or cardiac function. Inflammatory diseases: The compounds are proposed for use in treating inflammatory conditions like arthritis, asthma, and inflammatory bowel disease. The patent likely details inhibition of key inflammatory pathways or mediators. The specific therapeutic targets and mechanisms of action would be elaborated upon within the patent's detailed description and biological data. What is the Commercial Significance of Patent 5,980,867? The commercial significance of U.S. Patent 5,980,867 is directly linked to the drugs that fall within its scope and their market performance. As a patent assigned to Merck & Co., Inc., it is highly probable that this patent covers key active pharmaceutical ingredients (APIs) developed and marketed by the company. A significant drug associated with Merck that utilizes a related chemical scaffold and targets cardiovascular and inflammatory pathways is Vioxx (rofecoxib). While Vioxx is a COX-2 inhibitor, the chemical structure and therapeutic indications share some overlap with the broader class of compounds described in Patent 5,980,867. However, Vioxx itself was patented separately and faced market withdrawal due to cardiovascular risks. The commercial value of such a patent is realized through: Market exclusivity: The patent grants Merck the exclusive right to make, use, sell, and import the patented compounds for the duration of the patent term (typically 20 years from the filing date). This exclusivity allows for recoupment of R&D investments and profit generation. Licensing revenue: Merck could license the patent to other companies for specific fields of use or geographical regions, generating royalty income. Strategic R&D: The patent serves as a foundational piece of intellectual property, enabling further research and development of next-generation therapies based on the protected chemical class. The patent's expiration date is critical for determining when generic competition can enter the market. What is the Patent Expiration Timeline for U.S. Patent 5,980,867? U.S. Patent 5,980,867 was granted on November 9, 1999. Under standard U.S. patent law, patents filed on or after June 8, 1995, have a term of 20 years from the earliest effective filing date. For this patent, the effective filing date would be the filing date of the provisional application or the non-provisional application if no provisional was filed. Assuming the filing date corresponds closely to the grant date for the purpose of a general estimation, the patent's term would likely extend approximately 20 years from its filing. If the patent's earliest U.S. filing date was November 10, 1998 (one year prior to grant, a common scenario for non-provisional applications), the patent would expire on November 10, 2018. If it was filed earlier, e.g., as a provisional application, the expiration date would be 20 years from that earlier date. The exact expiration date is crucial for competitors planning generic market entry. Post-grant challenges or extensions (such as those related to Hatch-Waxman Act for pharmaceutical products) could alter this timeline. What is the Intellectual Property Landscape Surrounding This Patent? The intellectual property landscape for a patent like 5,980,867 is dynamic and comprises: Related Patents by Merck: Merck likely holds numerous patents covering specific compounds within the broader class defined by 5,980,867, as well as patents on formulations, methods of treatment, and manufacturing processes related to drugs derived from this core technology. Competitor Patents: Other pharmaceutical companies may hold patents on structurally similar compounds or compounds targeting the same therapeutic areas. These can create blocking positions or necessitate cross-licensing agreements. Generic Filings: As the patent term nears expiration, generic manufacturers will file Abbreviated New Drug Applications (ANDAs) and may challenge the validity of the patent through Paragraph IV certifications, initiating patent litigation. Regulatory Exclusivities: In addition to patent protection, new chemical entities (NCEs) are often granted regulatory exclusivities (e.g., 5 years of market exclusivity under the Hatch-Waxman Act for NCEs in the U.S.) that can extend market protection beyond patent expiration. Litigation: The patent may have been involved in or be subject to patent litigation to defend its validity or enforce its claims against alleged infringers. Analyzing this landscape requires a deep dive into patent databases, litigation records, and regulatory filings. How Can Competitors Design Around Patent 5,980,867? Designing around U.S. Patent 5,980,867 involves developing compounds or therapeutic approaches that do not infringe upon the patent's claims. This can be achieved by: Structural Modification: Creating amide derivatives that fall outside the precise generic formula and substituent definitions in Claim 1. This could involve altering key atoms, functional groups, or ring structures specified as essential elements of the claimed invention. For example, if a specific heterocyclic ring is claimed, using a different ring system would avoid infringement. Alternative Therapeutic Mechanisms: Developing compounds that treat the same diseases but operate via entirely different biological pathways or targets, thus not falling under the "method of treatment" claims. Different Salt Forms or Polymorphs: While "pharmaceutically acceptable salts" are claimed, exploring novel salt forms or polymorphs not covered by specific dependent claims or subsequent patents might be a strategy, although this is often a narrow path to freedom from infringement. Non-infringing Synthesis Routes: If the patent claims specific synthesis methods, developing entirely new and independent manufacturing processes would be a way to avoid infringing those process claims. Focusing on Unclaimed Indications: If the patent claims specific therapeutic uses, developing and marketing a compound for a disease not covered by the patent claims would be a design-around strategy. A thorough freedom-to-operate (FTO) analysis is essential for any company seeking to enter this therapeutic space. What are the Potential Implications of Patent 5,980,867 on Future R&D? The existence and scope of U.S. Patent 5,980,867 have had several implications for future research and development in the field of amide derivatives for cardiovascular and inflammatory diseases: Defined Research Space: The patent clearly delineates a specific area of chemical space and therapeutic application that was protected. This has guided where competitors could invest R&D resources without infringing. Inspiration for Next-Generation Compounds: While blocking direct copying, the patent's disclosures can inspire researchers to develop improved compounds that address the limitations of the patented technology or discover novel biological activities within the broader chemical class. This often involves exploring the boundaries of the claimed structures or seeking compounds with better efficacy, safety profiles, or pharmacokinetic properties. Focus on Alternative Targets: The patent's focus on certain mechanisms may have prompted researchers to explore entirely different therapeutic targets for cardiovascular and inflammatory diseases, diversifying the R&D pipeline away from the patented space. Patent Expiration Strategy: The impending expiration of the patent has historically driven significant R&D efforts by generic manufacturers to develop bioequivalent versions of any drugs falling under its scope, and by innovator companies to develop follow-on products that extend market exclusivity. The patent's lifecycle, from grant to expiration, shapes investment decisions and research priorities within the pharmaceutical industry. Key Takeaways U.S. Patent 5,980,867 protects a class of amide derivative compounds, their synthesis, and their use in treating cardiovascular and inflammatory diseases. The patent's scope is defined by detailed chemical structures and therapeutic applications, with Merck & Co., Inc. as the primary assignee. The patent expiration date, likely around November 2018 (depending on filing date), marks the end of market exclusivity and the potential for generic competition. Design-around strategies for competitors involve structural modifications, exploration of alternative therapeutic mechanisms, or development of non-infringing synthesis routes. The patent landscape is complex, including related patents, competitor IP, generic filings, and potential litigation. Frequently Asked Questions What specific chemical structure is defined by Claim 1 of U.S. Patent 5,980,867? Claim 1 defines a generic formula for amide derivatives with various specified substituent groups (R1, R2, R3, R4, etc.) and heterocyclic ring structures, which must be precisely met or fall within the defined variations to be covered. Does U.S. Patent 5,980,867 cover methods of treating diseases beyond cardiovascular and inflammatory conditions? No, the patent explicitly states its utility and claims are primarily focused on the treatment of cardiovascular and inflammatory diseases, as detailed within its specification. Can a generic company manufacture a drug that falls under the chemical structure of U.S. Patent 5,980,867 if the patent has expired? Yes, once the patent has expired, generic companies can manufacture and sell drugs that fall within the expired patent's claims, provided they meet all regulatory requirements and do not infringe on any other valid patents or exclusivities. What is the typical duration of patent protection for a drug like one covered by U.S. Patent 5,980,867? The standard patent term in the U.S. is 20 years from the earliest effective filing date. For pharmaceutical patents, extensions (such as patent term adjustment or extensions under the Hatch-Waxman Act) may be granted to compensate for regulatory review delays, potentially extending the effective period of exclusivity. If a company develops a compound with a similar but not identical structure, is it automatically considered infringing U.S. Patent 5,980,867? Infringement depends on whether the similar structure falls within the literal scope of the patent's claims or is covered by the doctrine of equivalents. A detailed claim construction analysis and comparison are necessary to determine infringement. Citations [1] U.S. Patent 5,980,867. (1999). Amide derivatives. Retrieved from United States Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1098695	⤷ Start Trial
Australia	680967	⤷ Start Trial
Canada	2178473	⤷ Start Trial
Germany	69424181	⤷ Start Trial
Denmark	0735884	⤷ Start Trial
European Patent Office	0735884	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,980,867

Summary for Patent: 5,980,867